- Home
- BCH vs EXEL Comparison
BCH vs EXEL Comparison
Compare BCH & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCH
- EXEL
- Stock Information
- Founded
- BCH 1893
- EXEL 1994
- Country
- BCH Chile
- EXEL United States
- Employees
- BCH N/A
- EXEL N/A
- Industry
- BCH Commercial Banks
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCH Finance
- EXEL Health Care
- Exchange
- BCH Nasdaq
- EXEL Nasdaq
- Market Cap
- BCH 11.7B
- EXEL 10.0B
- IPO Year
- BCH 2002
- EXEL 2000
- Fundamental
- Price
- BCH $22.87
- EXEL $33.29
- Analyst Decision
- BCH Hold
- EXEL Buy
- Analyst Count
- BCH 1
- EXEL 16
- Target Price
- BCH $21.00
- EXEL $32.75
- AVG Volume (30 Days)
- BCH 282.0K
- EXEL 2.1M
- Earning Date
- BCH 02-03-2025
- EXEL 02-04-2025
- Dividend Yield
- BCH 7.40%
- EXEL N/A
- EPS Growth
- BCH 14.90
- EXEL 441.02
- EPS
- BCH 0.02
- EXEL 1.55
- Revenue
- BCH $3,231,399,879.00
- EXEL $2,081,598,000.00
- Revenue This Year
- BCH N/A
- EXEL $20.59
- Revenue Next Year
- BCH $1.83
- EXEL $1.50
- P/E Ratio
- BCH $7.25
- EXEL $21.51
- Revenue Growth
- BCH 10.24
- EXEL 17.31
- 52 Week Low
- BCH $20.93
- EXEL $19.20
- 52 Week High
- BCH $25.97
- EXEL $36.97
- Technical
- Relative Strength Index (RSI)
- BCH 42.69
- EXEL 40.46
- Support Level
- BCH $22.53
- EXEL $34.58
- Resistance Level
- BCH $23.74
- EXEL $36.22
- Average True Range (ATR)
- BCH 0.33
- EXEL 0.80
- MACD
- BCH -0.03
- EXEL -0.44
- Stochastic Oscillator
- BCH 27.69
- EXEL 5.79
About BCH Banco De Chile ADS
Operating under three separate brand names (Banco de Chile, Banco Edwards-Citi, and Banco CrediChile) Banco de Chile is the second largest in the country by loans and third largest by deposits. Banco de Chile generates most of its net interest income (roughly 60% of total revenue) from its mortgage, unsecured consumer credit lines, and commercial loans, with 25% of its outstanding loans being made to firms with more than 10,000 million CLP in revenue. Outside of its banking business, Banco de Chile is the largest asset manager in the country and one of the largest security brokerages, supporting its substantial fee-based revenue.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.